Effect of F8 B domain gene variants on synthesis, secretion, activity and stability of factor VIII protein

Summary

The B domain of the coagulation factor (F)VIII comprises some unique characteristics. Though the B domain is important for processing, intracellular transport and secretion of FVIII protein, its role in the coagulation still remains unclear. This study aims to investigate the influence of 19 reported B domain variants on quantity and quality of expressed FVIII protein. F8 variants were transiently expressed in HEK293T cells. Media and cell lysates were collected after 72 hours. FVIII synthesis, relative secretion, activity and thermostability were analysed in comparison to FVIII wild-type. Eleven of 19 analysed B domain variants showed normal FVIII activity (FVIII:C), and antigen values (40–150 %). Eight variants exhibited a decreased FVIII:C, corresponding to a mild phenotype most likely due to impaired expression and secretion mechanism, reduced thermostability or combined mechanisms. One variant, p.His1066Tyr, showed markedly reduced FVIII antigen in cell lysate. The variants p.Asp845Glu, p.His998Gln, and p.Ala1610Ser revealed a significantly decreased relative secretion. Additionally, six B domain variants significantly reduced stability of FVIII. In conclusion, none of the analysed missense mutations was causative for a severe haemophilia A (HA) phenotype. Nevertheless, the mutations p.Asp845Glu, p.Pro947Arg, p.Glu1057Lys, p.His1066Tyr, p.Arg1126Trp, p.Arg1329His, p.Leu1481Pro, and p.Ala1610Ser resulted in decreased FVIII:C values that may explain mild HA phenotypes.

Keywords

Factor VIII - B domain - missense mutation - genotype-phenotype relationship

• References

• 1 Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998; 92: 3983-3996.
• 2 White 2nd GC, Rosendaal F, Aledort LM. et al. Definitions in haemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardisation committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost 2001; 85: 560.
• 3 Fay PJ. Activation of factor VIII and mechanisms of cofactor action. Blood Rev 2004; 18: 1-15.
• 4 Pipe SW. Functional roles of the factor VIII B domain. Haemophilia 2009; 15: 1187-1196.
• 5 Goodeve AC, Peake IR. The molecular basis of haemophilia A: genotype-phe-notype relationships and inhibitor development. Semin Thromb Haemost 2003; 29: 23-30.
• 6 Schwaab R, Oldenburg J, Schwaab U. et al. Characterisation of mutations within the factor VIII gene of 73 unrelated mild and moderate haemophiliacs. Br J Haematol 1995; 91: 458-464.
• 7 Higuchi M, Antonarakis SE, Kasch L. et al. Molecular characterisation of mild-to-moderate haemophilia A: detection of the mutation in 25 of 29 patients by denaturing gradient gel electrophoresis. Proc Natl Acad Sci USA 1991; 88: 8307-8311.
• 8 Schatz SM, Zimmermann K, Hasslacher M. et al. Mutation of the surface-exposed amino acid Trp to Ala in the FVIII C2 domain results in defective secretion of the otherwise functional protein. Br J Haematol 2004; 125: 629-637.
• 9 Spiegel PC, Murphy P, Stoddard BL. Surface-exposed haemophilic mutations across the factor VIII C2 domain have variable effects on stability and binding activities. J Biol Chem 2004; 279: 53691-53698.
• 10 Leyte A, Schijndel van HB, Niehrs C. et al. Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol Chem 1991; 266: 740-746.
• 11 Tuddenham EG, Schwaab R, Seehafer J. et al. Haemophilia A: database of nu-cleotide substitutions, deletions, insertions and rearrangements of the factor VIII gene, second edition. Nucleic Acids Res 1994; 22: 4851-4868.
• 12 Gitschier J, Kogan S, Levinson B. et al. Mutations of factor VIII cleavage sites in haemophilia A. Blood 1988; 72: 1022-1028.
• 13 Reitter S, Sturn R, Horvath B. et al. Spectrum of causative mutations in patients with haemophilia A in Austria. Thromb Haemost 2010; 104: 78-85.
• 14 Chan V, Pang A, Chan TP. et al. Molecular characterisation of haemophilia A in southern Chinese. Br J Haematol 1996; 93: 451-456.
• 15 Habart D, Kalabova D, Novotny M. et al. Thirty-four novel mutations detected in factor VIII gene by multiplex CSGE: modeling of 13 novel amino acid substitutions. J Thromb Haemost 2003; 1: 773-781.
• 16 Jayandharan G, Shaji RV, Baidya S. et al. Identification of factor VIII gene mutations in 101 patients with haemophilia A: mutation analysis by inversion screening and multiplex PCR and CSGE and molecular modelling of 10 novel missense substitutions. Haemophilia 2005; 11: 481-491.
• 17 Becker J, Schwaab R, Moller-Taube A. et al. Characterisation of the factor VIII defect in 147 patients with sporadic haemophilia A: family studies indicate a mutation type-dependent sex ratio of mutation frequencies. Am J Hum Genet 1996; 58: 657-670.
• 18 El-Maarri O, Singer H, Klein C. et al. Lack of F8 mRNA: a novel mechanism leading to haemophilia A. Blood 2006; 107: 2759-2765.
• 19 Castaman G, Giacomelli SH, Mancuso ME. et al. Deep intronic variations may cause mild haemophilia A. J Thromb Haemost 2011; 9: 1541-1548.
• 20 Schwarz HP, Lenting PJ, Binder B. et al. Involvement of low-density lipoprotein receptor-related protein (LRP) in the clearance of factor VIII in von Willebrand factor-deficient mice. Blood 2000; 95: 1703-1708.
• 21 Ogata K, Selvaraj SR, Miao HZ. et al. Most factor VIII B domain missense mutations are unlikely to be causative mutations for severe haemophilia A: implications for genotyping. J Thromb Haemost 2011; 9: 1183-1190.
• 22 Nossent AY, Eikenboom JC, Tanis BC. et al. Haplotypes encoding the factor VIII 1241Glu variation and the risk of myocardial infarction. J Thromb Haemost 2007; 5: 619-621.
• 23 Viel KR, Machiah DK, Warren DM. et al. A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels. Blood 2007; 109: 3713-3724.
• 24 Roelse JC, De Laaf RT, Timmermans SM. et al. Intracellular accumulation of factor VIII induced by missense mutations Arg593-->Cys and Asn618-->Ser explains cross-reacting material-reduced haemophilia A. Br J Haematol 2000; 108: 241-246.
• 25 Pipe SW, Kaufman RJ. Factor VIII C2 domain missense mutations exhibit defective trafficking of biologically functional proteins. J Biol Chem 1996; 271: 25671-25676.
• 26 Guillet B, Lambert T, d’Oiron R. et al. Detection of 95 novel mutations in coagulation factor VIII gene F8 responsible for haemophilia A: results from a single institution. Hum Mutat 2006; 27: 676-685.
• 27 Konkle BA, Josephson NC, Nakaya Fletcher SM. et al. Haemophilia A, GeneReviews™ [Internet]. Seattle (WA): University of Washington, Seattle; 1993. 2013
• 28 Zhang YZ, Liu JX, Shao HZ. et al. Characterisation of genetic defects of haemophilia A in mainland China. Genet Anal 1999; 15: 205-207.
• 29 Awidi A, Ramahi M, Alhattab D. et al. Study of mutations in Jordanian patients with haemophilia A: identification of five novel mutations. Haemophilia 2010; 16: 136-142.
• 30 Santacroce R, Acquila M, Belvini D. et al. Identification of 217 unreported mutations in the F8 gene in a group of 1,410 unselected Italian patients with haemophilia A. J Hum Genet 2008; 53: 275-284.
• 31 McGinniss MJ, Kazazian Jr. HH, Hoyer LW. et al. Spectrum of mutations in CRM-positive and CRM-reduced haemophilia A. Genomics 1993; 15: 392-398.
• 32 Abu-Amero KK, Hellani A, Al-Mahed M. et al. Spectrum of factor VIII mutations in Arab patients with severe haemophilia A. Haemophilia 2008; 14: 484-488.
• 33 Bogdanova N, Markoff A, Pollmann H. et al. Spectrum of molecular defects and mutation detection rate in patients with severe haemophilia A. Hum Mutat 2005; 26: 249-254.
• 34 Liu M, Murphy ME, Thompson AR. A domain mutations in 65 haemophilia A families and molecular modelling of dysfunctional factor VIII proteins. Br J Haematol 1998; 103: 1051-1060.